TPST-2003 / Tempest Therap - LARVOL DELTA

TPST-2003: dual CD19/BCMA CAR-T program (GlobeNewswire) - "Phase 1 complete in patients with relapsed multiple myeloma ('rrMM'), with data expected in 2026 and a biologics license application ('BLA') in China planned for 2027;Phase 1 currently enrolling patients with POEMs syndrome, with data expected in 2027 and a BLA in China planned for 2028; Tempest will have global rights to TPST-2003 outside of China, India, Turkey and Russia, and plans to pursue a potential registrational study in rrMM in the U.S. starting in 2027; Data from Chinese pivotal study expected to validate probability of success for Tempest program, and rights will include the right to reference data generated in support of the planned China BLA."

China filing • Clinical data • New trial • Trial completion • Hematological Disorders • Multiple Myeloma

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire) - "Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term)...The Proposed Transaction will expand and further diversify Tempest’s existing clinical-stage pipeline, with the acquisition of the first clinical-stage CD19/BCMA parallel structured dual-CAR T specifically designed to target patients with extramedullary disease (EMD), which we are referring to as TPST-2003...Tempest plans to pursue business development discussions or an additional financing to advance the pivotal development of amezalpat (TPST-1120) in first-line liver cancer ('HCC')....Plan to continue the development of additional new preclinical and research-stage pipeline programs: TPST-2206: dual-targeting CD70/CD70 CAR-T for renal cell carcinoma; TPST-3003: allogeneic dual-targeting CD19/BCMA; TPST-3206: allogeneic dual-targeting CD70/CD70."

M&A • Genetic Disorders • Hepatocellular Cancer • Multiple Myeloma • Renal Cell Carcinoma • Systemic Lupus Erythematosus